a modified version 8 of the GRADE 11 system to rate the quality of the evidence for each outcome and to determine the overall strength of each recommendation. Guideline recommendations were finalized based on consensus of the GDG. Patient-oriented outcomes were prioritized in the guideline recommendations.
Outcomes assessed included maintenance of ventricular rate and sinus rhythm; symptom relief; quality of life; all-cause and cardiovascular mortality; stroke; systemic embolism; cardiovascular events; hospitalizations; major and minor bleeding; and other adverse events due to medications. The recommendations were worded to reflect the strength and direction of the recommendation, and the quality of the evidence was listed parenthetically. Tables and quantitative risk information provided the risks and benefits of different medications as well as the evaluation of the evidence for patient-centered outcomes to facilitate shared decision-making between patients and their primary care clinicians.
The purpose of this updated guideline is to provide clinical recommendations for primary care physicians to pharmacologically manage atrial fibrillation based on the available evidence. While other treatments, such as surgery, were deemed outside the scope of this guideline, family physicians should be aware of the full range of options and discuss these with their patients. Symptoms in the majority of patients with AF can be managed pharmacologically using a lenient rate-control strategy. The preferred treatment options for rate control include non-dihydropyridine calcium channel blockers and beta blockers. In patients with atrial fibrillation and additional risk factors for stroke, chronic anticoagulation is recommended. Prior to initiating treatment, clinicians should discuss the benefits and harms of the different anticoagulants, including potential medication cost, lifestyle modifications, and risk of bleeding. Careful risk assessment is essential, as patients with a low risk of stroke may not be appropriate for anticoagulation. Due to the increased risk of bleeding, dual therapy with aspirin and anticoagulants should be avoided. The specific recommendation statements are outlined below.
Recommendation 1:
The AAFP strongly recommends rate control in preference to rhythm control for the majority of patients who have atrial fibrillation (strong recommendation, moderate quality evidence). Preferred options for rate-control therapy include non-dihydropyridine calcium channel blockers and beta blockers. Rhythm control may be considered for certain patients based on patient symptoms, exercise tolerance, and patient preferences (weak recommendation, low quality evidence).
Recommendation 2:
The AAFP recommends lenient rate control (<110 beats per minute resting) over strict rate control (<80 beats per minute resting) for patients who have atrial fibrillation (weak recommendation, low quality evidence).
Recommendation 3:
The AAFP recommends that clinicians discuss the risk of stroke and bleeding with all patients considering anticoagulation (good practice point). Clinicians should consider using the continuous CHADS 2 or continuous CHA 2 DS 2 -VASc for prediction of risk of stroke (weak recommendation, low quality evidence) and HAS-BLED for prediction of risk for bleeding (weak recommendation, low quality evidence) in patients who have atrial fibrillation.
Recommendation 4:
The AAFP strongly recommends that patients who have atrial fibrillation receive chronic anticoagulation unless they are at low risk of stroke (CHADS 2 <2) or have specific contraindications (strong recommendation, high quality evidence). Choice of anticoagulation therapy should be based on patient preferences and patient history. Options for anticoagulation therapy may include warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban.
Recommendation 5:
The AAFP strongly recommends against dual treatment with anticoagulant and antiplatelet therapy in most patients who have atrial fibrillation (strong recommendation, moderate quality evidence).
For further reading on the evidence and recommendations and to see the shared-decision making tables, please refer to the AAFP summary and full guideline here: http://www.aafp.org/patient-care/ clinical-recommendations/all/atrial-fibrillation. html. For further information with notes from a guideline author, please refer to the AAFP News story here: http://www.aafp.org/news/health-of-thepublic/20170605afibguideline.html.
Note: These recommendations are provided only as assistance for clinicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. All AAFP guidelines are scheduled for a review 5 years after completion, or sooner if new evidence becomes available. 
